Kualitas bukti 4.25/5
Skor tinjauan delapan dimensi terhadap rubrik kualitas . Setiap dimensi dinilai 1–5.
- D1 Dasar sumber
- 3/5
- D2 Otoritas sumber
- 5/5
- D3 Aritmetika
- 5/5
- D4 Ketidakpastian
- 3/5
- D5 Cakupan
- 4/5
- D6 Prosa
- 5/5
- D7 Kejujuran persepsi
- 4/5
- D8 Kelengkapan peringatan
- 5/5
≈ Sama mungkinnya dengan
Dipersepsikan
Kebanyakan orang memahami bahwa resistensi antibiotik adalah masalah dengan cara yang samar dan setingkat berita utama — sesuatu yang akan penting di masa depan, sebagian besar di rumah sakit, sebagian besar bagi orang lain. Gagasan bahwa lebih dari satu dari tiga orang dewasa AS akan mengalami infeksi serius yang resisten obat pada suatu titik dalam masa hidup mereka hampir sepenuhnya tidak ada dalam persepsi risiko awam. Resistensi dibingkai sebagai kegagalan kebijakan, bukan bahaya pribadi.
Sumber: intuisi redaksi, bukan hasil survei
Aktual
~2,8 juta infeksi resisten antibiotik per tahun di AS
Penduduk AS
Tampilkan perhitungan
Tingkat tahunan: 2.800.000 / 335.000.000 = 0,008358 per orang per tahun. Diakumulasikan selama 59 tahun dewasa: 1 - (1 - 0,008358)^59 = 1 - (0,99164)^59 ≈ 1 - 0,609 = 0,391. Ini adalah probabilitas mengalami setidaknya satu infeksi AR serius seumur hidup, memperlakukan setiap tahun sebagai penarikan independen pada tingkat populasi. 35.000 kematian tahunan akibat infeksi AR menghasilkan probabilitas AR fatal seumur hidup terpisah ~0,006 (1 dari 167). Angka utama mencakup infeksi serius (tidak semua episode berakhir dengan rawat inap), menurut definisi Laporan Ancaman AR 2019 CDC.
Catatan: Angka 2,8 juta adalah hitungan *kejadian* infeksi, bukan orang unik — seorang in…
Angka 2,8 juta adalah hitungan *kejadian* infeksi, bukan orang unik — seorang individu dapat menyumbang beberapa episode dalam setahun, sehingga membaginya dengan populasi AS melebih-lebihkan probabilitas tahunan per orang. Angka seumur hidup «lebih dari satu dari tiga orang dewasa AS» yang dihasilkan karenanya merupakan batas atas risiko pribadi, bukan estimasi per orang langsung. Perhitungan probabilitas majemuk selanjutnya memperlakukan insidensi tahunan sebagai independen lintas tahun, yang melebih-lebihkan risiko seumur hidup sebenarnya jika infeksi sebelumnya memberi kekebalan yang tahan lama atau jika infeksi berulang mengelompok pada subset pasien berisiko tinggi. Sebaliknya, perhitungan menggunakan tingkat populasi seluruh AS, yang meremehkan risiko bagi pengguna layanan kesehatan yang sering, penghuni fasilitas perawatan jangka panjang, dan individu immunocompromised. Lonjakan 20 % infeksi resisten yang timbul di rumah sakit pada era pandemi menunjukkan baseline 2019 mungkin kurang menghitung beban saat ini. Pembaruan CDC 2021-2022 lebih sempit cakupannya (enam patogen, timbul di rumah sakit saja) dan tidak dapat langsung menggantikan estimasi 2019.
Risiko terkait
Risiko lain dengan tema serupa — untuk menjelajahi ketakutan terkait.
Olahraga petualangan
Berapa kemungkinan cedera serius dari partisipasi rutin dalam selancar, sepeda gunung, atau panjat tebing?
Gangguan penggunaan alkohol
Berapa peluang mengembangkan gangguan penggunaan alkohol seumur hidup?
Kerusakan gigi akibat bruksisme
Seberapa besar kemungkinan mengalami kerusakan gigi yang signifikan secara klinis atau disfungsi sendi temporomandibular akibat bruksisme?
Risiko AUD warisan
Jika orang tua memiliki gangguan penggunaan alkohol, berapa kemungkinan Anda mengembangkan gangguan penggunaan alkohol sendiri?
Pilih penantang
The numbers here are large enough to feel implausible. CDC’s 2019 Antibiotic Resistance Threats Report counted more than 2.8 million serious antibiotic-resistant infections per year in the United States, resulting in more than 35,000 deaths. An independent systematic analysis of bloodstream infections published in 2023 found 60,813 deaths associated with bacterial AMR in the US in 2019 — a figure that, though narrower in scope (BSI only), underscores the severity of the resistance burden through a different methodology. Compounded over a 59-year adult lifespan, the population-level rate works out to roughly a 39% lifetime probability of experiencing at least one serious drug-resistant infection — closer to the odds of a coin flip than to the rare-disease framing that most people carry. The fatal subset is narrower: the 35,000 annual deaths translate to a lifetime fatal AR-infection probability of about 1 in 167.
The gap between perceived and actual risk exists partly because resistance is invisible at the clinical encounter. A patient prescribed a course of antibiotics for a UTI or skin infection rarely learns that the organism was resistant, only that the first drug did not work and a second was tried. The category of “infection that required escalation to a harder drug” is rarely coded as a patient-facing event — it shows up in microbiology lab records, not in the conversation most people remember. Resistance is also genuinely distributed unevenly: it concentrates in healthcare settings, in post-surgical patients, in the elderly and immunocompromised, and in communities with high antibiotic use and limited stewardship. The average healthy adult spending minimal time in clinical settings faces a lower per-year rate than the population mean; the math shifts considerably for anyone with a chronic condition that brings them into regular contact with the healthcare system.
The pandemic interval offers the clearest signal that this is not a problem that peaked and is now improving. CDC’s 2021-2022 update found that six hospital-onset resistant infections rose by a combined 20% compared to pre-pandemic levels, peaking in 2021 and remaining elevated in 2022. The mechanism is familiar — pandemic-era disruption to infection control, broad empirical antibiotic use in COVID patients, and delayed elective procedures that concentrated sicker patients in acute-care settings. The 2.8 million baseline is almost certainly a floor for current incidence, not a ceiling. The people at meaningfully elevated risk are not the worried healthy but rather the immunocompromised, the elderly in care facilities, the oncology patients, and anyone facing an invasive procedure — which, at some point, describes most adults.
Fakta terkait
AS mencatat sekitar 2,8 juta infeksi resisten antibiotik per tahun, risiko seumur hidup mendekati 1 dari 2,6 bagi orang dewasa AS. Sebagian besar dapat disembuhkan, tetapi angkanya jauh lebih tinggi dari dugaan publik.
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
2/2 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
-
[1] Centers for Disease Control and Prevention (CDC) — Antibiotic Resistance Threats in the United States, 2019 Terverifikasi
Antibiotic Resistance Threats in the United States, 2019- Statistik
More than 2.8 million antibiotic-resistant infections occur in the US each year, and more than 35,000 people die as a result- Kutipan
“"More than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. When Clostridioides difficile — a bacterium that is not typically resistant but can cause deadly diarrhea and is associated with antibiotic use — is added to these, the total reaches 3 million infections and 48,000 deaths." ”
- Data sumber dari
- 2019-11-13
- Diakses
- 2026-04-24 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- CDC's 2019 AR Threats Report is the most comprehensive national estimate of antibiotic-resistant infection burden. The 2.8 million figure covers 18 pathogens classified as urgent, serious, or concerning threats and is used as the native numerator. The 35,000 deaths figure anchors the fatal sub-probability in the assumptions. Subsequent CDC data (2021-2022 update) found that six hospital-onset resistant infections rose 20% during the COVID-19 pandemic peak, suggesting the 2.8M baseline is a floor, not a ceiling, for post-pandemic years.
-
[2] Open Forum Infectious Diseases / Oxford University Press — Burden of Bacterial Antimicrobial Resistance in United States in 2019: A Systematic Analysis Terverifikasi
Burden of Bacterial Antimicrobial Resistance in United States in 2019: A Systematic Analysis- Statistik
60,813 deaths associated with and 14,987 deaths attributable to bacterial AMR in bloodstream infections in the US in 2019- Kutipan
“"In the US, there were 60,813 deaths (95% uncertainty interval [UI]: 32,520–102,231) associated with and 14,987 deaths (95% UI: 7,712–25,156) attributable to bacterial AMR in blood stream infection highest in 2019." The paper concludes: "AMR is a serious burden in the United States, with millions of people acquiring antibiotic-resistant infections each year and tens of thousands dying as a result." ”
- Data sumber dari
- 2023-11-01
- Diakses
- 2026-04-24 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- This independent systematic analysis focuses on bloodstream infections (BSI) specifically, finding 60,813 deaths associated with and 14,987 deaths attributable to bacterial AMR in BSI in 2019. The scope is narrower than CDC's all-infection estimate (2.8M infections across 18 pathogens), but the BSI-specific death toll (60,813 associated) exceeds CDC's 35,000 attributable deaths across all infection types, reflecting different attribution methods. The peer-reviewed design — drawing on hospital discharge records, microbiology lab reports, and vital statistics — is methodologically independent of CDC's surveillance network. Used here as corroborating evidence for the severity of AR burden rather than the native numerator.
- Independensi
- Methodologically independent of CDC's Threats Report: different data sources (hospital discharge records vs. sentinel surveillance) and different attribution framework, making this a genuine cross-check rather than a recount of the same pipeline.